Mileshkin, L., Bochtler, T., Pauli, C., Durán-Pacheco, G., Arslan, C., Bigot, F., . . . Krämer, A. (2023). LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP). Annals of Oncology, 34, S1254. https://doi.org/10.1016/j.annonc.2023.10.006
Chicago Style (17th ed.) CitationMileshkin, L., et al. "LBA16 Primary Analysis of Efficacy and Safety in the CUPISCO Trial: A Randomised, Global Study of Targeted Therapy or Cancer Immunotherapy Guided by Comprehensive Genomic Profiling (CGP) Vs Platinum-based Chemotherapy (CTX) in Newly Diagnosed, Unfavourable Cancer of Unknown Primary (CUP)." Annals of Oncology 34 (2023): S1254. https://doi.org/10.1016/j.annonc.2023.10.006.
MLA (9th ed.) CitationMileshkin, L., et al. "LBA16 Primary Analysis of Efficacy and Safety in the CUPISCO Trial: A Randomised, Global Study of Targeted Therapy or Cancer Immunotherapy Guided by Comprehensive Genomic Profiling (CGP) Vs Platinum-based Chemotherapy (CTX) in Newly Diagnosed, Unfavourable Cancer of Unknown Primary (CUP)." Annals of Oncology, vol. 34, 2023, p. S1254, https://doi.org/10.1016/j.annonc.2023.10.006.
